Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 95-100

  Lindner, J L ^a   Loibl, S ^b,c   Denkert, Carsten ^a   Ataseven, B ^d   Fasching, P A ^e   Pfitzner, B M ^a   Gerber, B ^f   Gade, S ^b   Darb Esfahani, S ^a   Sinn, B V ^a   Huober, J ^g   Engels, K ^h   Tesch, H ⁱ   Karn, T ^j   Pommerenke, F ^k   Liedtke, C ^l   Untch, M ^m   Muller V ⁿ   Rack, B ^o   Schem, C ^p   Von Minckwitz, G ^b,j   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Breast Group   (Germany)

^c Klinikum Offenbach   (Germany)

^d KLINIKEN ESSEN MITTE   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f Klinikum Sudstadt   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h Zentrum für Pathologie Zytologie und Molekularpathologie   (Germany)

ⁱ Bethanien Krankenhaus Frankfurt   (Germany)

^j GOETHE UNIVERSITY   (Germany)

^k Klinikum Sudstadt   (Germany)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^m HELIOS KLINIKUM BERLIN BUCH   (Germany)

ⁿ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^o UNIVERSITY OF MUNICH   (Germany)

^p UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

Breast cancer; Neoadjuvant chemotherapy; PCR; SPARC

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; NAVELBINE; OSTEONECTIN; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SPARC PROTEIN, HUMAN; TAXOID; TUMOR MARKER;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; DISEASE ASSOCIATION; ECHOMAMMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT THERAPY; BIOSYNTHESIS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOADJUVANT THERAPY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; OSTEONECTIN; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922553334     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu487     Document Type: Article

References (26)

1. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 2004; 92: 679-690.
2. Tremble PM, Lane TF, Sage EH et al. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol 1993; 121: 1433-1444.
3. Rivera LB, Bradshaw AD, Brekken RA. The regulatory function of SPARC in vascular biology. Cell Mol Life Sci 2011; 68: 3165-3173.
4. Yan Q, Sage EH. SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 1999; 47: 1495-1506.
5. Sage EH, Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem 1991; 266: 14831-14834.
6. Sage H, Vernon RB, Funk SE et al. SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix. J Cell Biol 1989; 109: 341-356.
7. Koukourakis MI, Giatromanolaki A, Brekken RA et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003; 63: 5376-5380.
8. Watkins G, Douglas-Jones A, Bryce R et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 267-272.
9. Jones C, Mackay A, Grigoriadis A et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 2004; 64: 3037-3045.
10. Lien HC, Hsiao YH, Lin YS et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 2007; 26: 7859-7871.
11. von Minckwitz G, Blohmer JU, Raab G et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16: 56-63.
12. von Minckwitz G, Kummel S, Vogel P et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008; 100: 552-562.
13. von Minckwitz G, Kummel S, Vogel P et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100: 542-551.
14. von Minckwitz G, Blohmer JU, Costa SD et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013; 31: 3623-3630.
15. Remmele W, Hildebrand U, Hienz HA et al. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol 1986; 409: 127-147.
16. Budczies J, Klauschen F, Sinn BV et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 2012; 7: e51862.
17. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995; 146: 95-100.
18. Helleman J, Jansen MP, Ruigrok-Ritstier K et al. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 2008; 14: 5555-5564.
19. Graham JD, Balleine RL, Milliken JS et al. Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content. Eur J Cancer 1997; 33: 1654-1660.
20. Lakhani SR, Reis-Filho JS, Fulford L et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11: 5175-5180.
21. Azim HA, Jr, Singhal S, Ignatiadis M et al. Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis. PLoS One 2013; 8: e62451.
22. Sage H, Johnson C, Bornstein P. Characterization of a novel serum albuminbinding glycoprotein secreted by endothelial cells in culture. J Biol Chem 1984; 259: 3993-4007.
23. Desai NP, Trieu V, Hwang LY et al. Improved effectiveness of nanoparticle albuminbound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008; 19: 899-909.
24. Yardley DA. nab(R)-Paclitaxel mechanisms of action and delivery. J Control Release 2013; 170: 365-372.
25. Gradishar WJ, Krasnojon D, Cheporov S et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27: 3611-3619.
26. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albuminbound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-7803.